Korro Bio, Inc.

Item 5. Other Information.

During the three months ended September 30, 2026, the following officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, amended or terminated contracts, instructions or written plans for the purchase or sale of our securities that were intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (each, a “Rule 10b5-1 plan”): On July 24, 2026, Ram Aiyar, our Chief Executive Officer, President and Interim Chief Financial Officer, adopted a Rule 10b5-1 plan providing for the potential sale of up to 25,000 shares of our common stock issued upon the vesting and settlement of restricted stock units; this plan is scheduled to expire on January 21, 2028. On September 1, 2026, Todd Chappell, our Chief Operating Officer, adopted a Rule 10b5-1 plan providing for the potential sale of up to 13,944 shares of our common stock issued or issuable upon the vesting and settlement of restricted stock units, as well as up to 5,000 shares of our common stock issuable upon the exercise of stock options; this plan is scheduled to expire on September 3, 2027. On September 1, 2026, Jeffrey Cerio, our Senior Vice President, General Counsel and Corporate Secretary, adopted a Rule 10b5-1 plan providing for the potential sale of up to 18,842 shares of our common stock issued or issuable upon the vesting and settlement of restricted stock units; this plan is scheduled to expire on December 31, 2027.

During the three months ended September 30, 2026, none of our other officers or directors informed us that they adopted, modified orterminated a Rule 10b5-1 plan or a trading plan not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.